WO2012007555A2 - Nouveaux sels de ziprasidone et leur méthodes de formation - Google Patents

Nouveaux sels de ziprasidone et leur méthodes de formation Download PDF

Info

Publication number
WO2012007555A2
WO2012007555A2 PCT/EP2011/062080 EP2011062080W WO2012007555A2 WO 2012007555 A2 WO2012007555 A2 WO 2012007555A2 EP 2011062080 W EP2011062080 W EP 2011062080W WO 2012007555 A2 WO2012007555 A2 WO 2012007555A2
Authority
WO
WIPO (PCT)
Prior art keywords
ziprasidone
salt according
crystalline form
succinate
ascorbate
Prior art date
Application number
PCT/EP2011/062080
Other languages
English (en)
Other versions
WO2012007555A3 (fr
Inventor
Marek Leszek Glowka
Waldemar Maniukiewicz
Monika Oracz
Lech Swinder
Karol Sagol
Marcin Szulc
Original Assignee
Zaklady Farmaceutyczne Polpharma, S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zaklady Farmaceutyczne Polpharma, S. A. filed Critical Zaklady Farmaceutyczne Polpharma, S. A.
Publication of WO2012007555A2 publication Critical patent/WO2012007555A2/fr
Publication of WO2012007555A3 publication Critical patent/WO2012007555A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Definitions

  • the invention concerns new ziprasidone salts and their crystalline forms, a pharmaceutical composition containing these salts, and their uses.
  • United States Patent description US 4 831 031 discloses 5-[2-[4-(1 ,2-benzisothiazol-3-yl)-1 -piperazinyl]ethyl]-6-chloro-1 ,3-dihydro- 2H-indol-2-one hydrochloride in the form of hemihydrate, which is however hygroscopically unstable, which may cause problems with the weight of active ingredient during the process of tabletting or encapsulation.
  • Patent descriptions EP0584903, EP00586191 , EP0706524, EP0790236 and EP01029861 present various methods of ziprasidone synthesis, especially its hydrochloride monohydrate form, which due to its better hygroscopic stability is currently the most often used hydrochloride form, both amorphous and crystalline.
  • ziprasidone especially crystalline forms, which would be suitable for use in the pharmaceutical industry and in particular allow easy production of ziprasidone preparations in solid form, such as tablets, capsules, chewable tablets, powders etc. for oral administration.
  • a ziprasidone salt in a pure and crystalline form which would allow the manufacture of preparations meeting strict pharmaceutical standards.
  • the present invention relates to the discovery of moderately water-soluble salts of ziprasidone.
  • the salts of the herein disclosed have excellent properties to be used in industrial scale, and specially to be used in the formulation of solid oral form comprising such salts of ziprasidone. Firstly, they can be isolated in a solid form, even in a crystalline form, which is highly desirable for drugs which are to be formulated in a solid oral form. Furthermore, the salts provided by herein disclosed show an excellent stability per se for long periods of time without the need for special storage conditions. This good stability is also shown after after being formulated, for example, in oral dosage form. In addition to their good stability, the salts provided by herein disclosed show a good dissolution profile, but without showing a excessively hygroscopic. The salts herein disclosed are easy to filter and dry and they can be in a substantially pure form and/or isolated form. Another advantage of the salts herein disclosed is the fact that they can be obtained in process suitable for large-scale production.
  • a ziprasidone salt selected from a group comprising ziprasidone succinate and ziprasidone ascorbate.
  • a ziprasidone salt according to clause 1 characterized in that it is ziprasidone succinate.
  • a ziprasidone salt according to any one of the preceding clauses characterized in that it is ziprasidone succinate in crystalline form.
  • a ziprasidone salt according to any one of the preceding clauses characterized in that it is ziprasidone succinate in crystalline form with an X-ray powdered-crystal pattern comprising the following 2 ⁇ ( ⁇ 0.2) values measured using CuKa radiation: 8.3400, 12.5200, 16.7063, 21 .4300, 22.6379, 23.4339 and 25.1807.
  • a ziprasidone salt according to any one of the preceding clauses characterized in that it is ziprasidone succinate in crystalline form with an X-ray powdered-crystal pattern comprising the following 2 ⁇ ( ⁇ 0.2) values measured using CuKa radiation: 8.3400, 12.5200, 16.3644, 16.7063, 19.3528, 21 .4300, 22.6379, 23.3682, 23.4339, 24.6158, 25.1807, 25.368, 26.1065, 26.5365, 27.3895, 27.7657, 28.92 and 39.8769.
  • a ziprasidone salt according to any one of the preceding clauses characterized in that it is ziprasidone salt has a mean particle size from 10 to 90 microns.
  • a ziprasidone salt according to clause 1 characterized in that it is ziprasidone ascorbate.
  • a ziprasidone salt according to the preceding clause characterized in that it is ziprasidone ascorbate in a solid form.
  • a ziprasidone salt according to any one of the two preceding clauses characterized in that it is ziprasidone ascorbate in crystalline form.
  • a ziprasidone salt according to any one of the three preceding clauses characterized in that it is crystalline form I with an X-ray powdered-crystal pattern comprising the following 2 ⁇ ( ⁇ 0.2) values measured using CuKa radiation: 12.6428, 15.9127, 19.7082, 20.3825, 20.91 16 and 25.6078.
  • a ziprasidone salt according to the preceding clause characterized in that it is crystalline form I with an X-ray powdered-crystal pattern comprising the following 2 ⁇ ( ⁇ 0.2) values measured using CuKa radiation: 7.2806, 12.6428, 12.7479, 15.9127, 19.1654, 19.7082, 20.3825, 20.91 16, 21 .6101 , 23.9734, 25.6078, 26.1883; 26.2496, 28.7584 and 31 .739.
  • a ziprasidone salt according to clauses 9 to 1 1 characterized in that it is crystalline form II with an X-ray powdered-crystal pattern comprising the following 2 ⁇ ( ⁇ 0.2) values measured using CuKa radiation: 18.0934, 20.2581 , 21 .6581 , 22.7161 and 25.2264.
  • a ziprasidone salt according to the preceding clause characterized in that it is crystalline form II with an X-ray powdered-crystal pattern comprising the following 2 ⁇ ( ⁇ 0.2) values measured using CuKa radiation: 14.8648, 17.719, 17.9232, 18.0934, 18.9212, 20.2581 , 21 .6581 , 22.7161 , 23.9379, 25.2264, 25.4468, 26.8346, 28.7283, 29.2495 and 29.862.
  • a pharmaceutical composition comprising an active substance and at least a pharmaceutically acceptable carrier, characterised in that the active substance is a ziprasidone salt of any one clauses 1 to 15, in particular in its crystalline form specified in clauses 4 and 1 1 .
  • a pharmaceutical composition according to the preceding clause characterised in that it is in oral dosage form.
  • the method for the manufacture of a pharmaceutical composition comprising at least the steps of: a) Preparation of binder solution, preferably with an aqueous solvent, preferably water; b) Spraying the binder solution onto the mixture to form a granulate; c) Drying the granulate at inlet temperature equal to or below 70°C, preferably below 60°C; d) Sizing the dried granules, preferably through a 1 mm mesh screen; e) Mixing the granules with the rest of the pharmaceutical acceptable excipients; and f) either compressing the granulate to form a tablet, and optionally coating, or filling the capsules with the granulate. 29.
  • the subject of the invention is a ziprasidone salt selected from a group comprising ziprasidone succinate and ziprasidone ascorbate. Salts according to the invention may occur in any form, especially amorphous or various crystalline forms and/or solvates.
  • a ziprasidone salt according to the invention is ziprasidone succinate in crystalline form.
  • ziprasidone succinate in crystalline form with an X-ray powdered -crystal pattern comprising the following 2 ⁇ ( ⁇ 0.2) values measured using CuKa radiation: 8.3400, 12.5200, 16.3644, 16.7063, 19.3528, 21 .4300, 22.6379, 23.3682, 23.4339, 24.6158, 25.1807, 25.368, 26.1065, 26.5365, 27.3895, 27.7657, 28.92 and 39.8769.
  • a ziprasidone salt according to the invention is a crystalline form containing ziprasidone ascorbate, and preferably it is crystalline form I with an X- ray powdered-crystal pattern comprising the following 2 ⁇ ( ⁇ 0.2) values measured using CuKa radiation: 7.2806, 12.6428, 12.7479, 15.9127, 19.1654, 19.7082, 20.3825, 20.91 16, 21 .6101 , 23.9734, 25.6078, 26.1883; 26.2496, 28.7584 and 31 .739, or crystalline form II with an X-ray powdered-crystal pattern comprising the following 2 ⁇ ( ⁇ 0.2) values measured using CuKa radiation: 14.8648, 17.719, 17.9232, 18.0934, 18.9212, 20.2581 , 21 .6581 , 22.7161 , 23.9379, 25.2264, 25.4468, 26.8346, 28.7283, 29.2495 and 29.862.
  • ziprasidone may be synthesised in the form of new salts according to the invention, in particular in crystalline form.
  • new ziprasidone salts according to the invention may be easily obtained in crystalline form and are better soluble than both ziprasidone in base form and its hydrochloride.
  • Another subject of the invention is a pharmaceutical composition containing an active substance and a pharmaceutically acceptable carrier, where the active substance is a ziprasidone salt according to the invention as described above, in particular in crystalline form as described above.
  • Another subject of the invention is the use of a ziprasidone salt according to the invention as described above, in particular in crystalline form as described above, to manufacture a pharmaceutical composition to treat or prevent mental illnesses, in particular schizophrenia, and their accompanying symptoms.
  • this invention provides two new ziprasidone salts which may be obtained in preferred crystalline forms.
  • the new salts are better soluble than the previously known forms of ziprasidone and its salts, and can be easily obtained in crystalline form using the disclosed methods which are suitable for use in the pharmaceutical industry.
  • the ziprasidone salts thus obtained may be administered as a pharmaceutical, especially for the treatment of schizophrenia. It may be administered to humans either as the compound itself or preferably admixed with pharmaceutically acceptable carriers or excipients in a pharmaceutical composition, in accordance with standard pharmaceutical practice.
  • the salts may be administered orally or parenterally, which includes, but is not limited to, intravenous and intramuscular administration.
  • Relevant pharmaceutical carriers include solid excipients and/or fillers as well as sterile aqueous solutions and various organic solvents.
  • Pharmaceutically acceptable carriers for the manufacture of pharmaceutical compositions containing compounds according to herein disclosed may be either liquids or solids. Solid preparations include powders, tablets, pills, capsules, cachets, suppositories and dispersed granules.
  • Solid carriers may include one or more substances, which may also act as diluents, flavouring agents, solubilising agents, lubricating agents, digesting agents, binders, preservatives, or agents for disintegrating the tablet or capsule material.
  • a solid oral form comprising that salts of the herein disclosed has a good dissolution profile without the need of reducing the particle size and/or adding additional excipients, as for instance surfactants.
  • a carrier in the form of finely ground solid is mixed with a finely ground active ingredient.
  • the active ingredients is admixed with a carrier having the required binding properties, in appropriate proportion, and then pressed into the required size and shape.
  • powders and tablets contain between 2 or 10 to circa 70 percent active compound.
  • Appropriate carriers include: magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth gum, methylcellulose, sodium carboxymethylcellulose, low-melting waxes, cocoa butter etc.
  • the term "manufacture" includes an active compound preparation with the encapsulating material as a carrier, which constitutes a capsule in which the active ingredient, with or without other carriers, is surrounded with a carrier, which is thus bound to the active ingredient. This also pertains to cachets and chewable tablets. Tablets, powders, pills, capsules, cachets and chewable tablets may be used in the form of solid dosages appropriate for oral administration.
  • a low-melting wax is melted, such as a mixture of fatty acid or cocoa butter glycerides, and then the active ingredient is homogenously dispersed into the wax on mixing. Next, the melted homogenous mixture is poured into forms of appropriate size and left to cool and thus solidify.
  • Liquid preparations include solutions, suspensions, intermittent infusions and emulsions, e.g. aqueous solutions or aqueous propylene glycol solutions.
  • liquid preparations may be prepared in the form of aqueous solutions of propylene glycol.
  • Aqueous solutions suitable for oral administration may be prepared by dissolving the active ingredient in water and adding, if necessary, appropriate dyes, flavouring, stabilizers and thickeners.
  • Aqueous suspensions suitable for oral administration may be prepared by dispersing a finely ground active ingredient in water with a viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose or other well-known agents for suspension formation.
  • a viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose or other well-known agents for suspension formation.
  • Solid preparations intended to be transformed, shortly before use, into liquid preparations for oral administration Such liquid forms include solutions, suspensions and emulsions.
  • Such preparations may also contain dyes, flavouring agents, stabilizers, buffers, natural and artificial sweeteners, dispersing agents, thickeners, solubilising agents etc.
  • a pharmaceutical preparation occurs in a form suitable for combined dosage.
  • the preparation is divided into unit doses containing an appropriate amount of the active ingredient.
  • the form intended for combined dosage may be a packaged preparation containing separated amounts of the preparation, such as packaged tablets or capsules, or powders in vials or ampoules.
  • a unit dose may also consist of a single capsule, tablet, cachet or chewable tablet, or a suitable number of any of such packaged forms.
  • the amount of the active ingredient in a unit dose of a preparation may vary or may be adjusted between 0.5-100 mg, preferably, 2.5-80 mg, depending on the type of use and the active ingredient strength.
  • the more preferably dosage form unit is from 10 to 80 mg per unit, specially for oral dosage forms. If required, the composition may also contain other compatible therapeutic agents.
  • new ziprasidone salts are administered at an initial dose of between 2.5 mg and ca. 80 mg daily.
  • the preferred daily dose varies between ca. 2.5 mg and ca. 20 mg.
  • dosage may vary depending on patient's needs, stadium of the illness treated and the type of compound used. Establishing the appropriate dosage in a given case depends on the doctor. Usually, treatment begins with a lower dosage which is below the optimum dosage for the compound. Then the dosage is increased in small increments until the optimum effect in the given circumstances is achieved. It may be useful to divide the total daily dose and administer it in portions throughout the day, if appropriate. Brief description of the drawings
  • Fig. 1 X-ray pattern of ziprasidone (free amine),
  • Fig. 1 1 DSC curve for ziprasidone ascorbate, form I,
  • Fig. 14 diffractogram of ziprasidone succinate. Examples
  • Ziprasidone and THF were added to a round-bottomed flask and maintained at a temperature of 60°C while stirring the solution with a magnetic stirrer for 1 hour.
  • Upon complete dissolution of ziprasidone into a clear solution five-time excess of ascorbic acid (in relation to ziprasidone) was added.
  • the reaction mixture was kept at a temperature of 60°C for one and a half hours, then activated carbon was added and the entire mixture was stirred for another half an hour.
  • the hot solution was filtered through celite. The clear solution obtained was left overnight at room temperature in order to crystallize.
  • the solution was inoculated with ziprasidone ascorbate crystals. Excess solvent was then evaporated. The precipitate was filtered off under vacuum, and excess ascorbic acid used for synthesis was washed out with water.
  • the reaction product was dried at 40°C. The reaction yield was ca. 78%.
  • the precipitate obtained was filtered off on a vacuum filter and washed with water to remove excess ascorbic acid used for synthesis. Wet product was dried at a temperature of 40°C for two hours.
  • the sample was ground in an agate mortar and then about 300 mg of the substance was placed in a sample holder of 16 mm in diameter and 2.4 mm in thickness. The sample was gently pressed from the back to produce a flat surface. The sample thus prepared was placed in an automatic (15-position) sample feeder. The measurement was taken at a temperature of 22°C.
  • the measurement was made using a PANanalytical X'Pert PRO MPD multi-task polycrystalline diffractometer. CuKa radiation was used, obtained by monochromatization of X-rays using a nickel filter. Continuous scan was used (step 0.0084°), measurement time for each step was 30 seconds. Measurements were made at 2 ⁇ ( ⁇ 0.2) from 3.5 to 55°.
  • Figures 1 , 2, 3 and 4 present X-ray patterns obtained during measurements for, respectively, free ziprasidone base, ziprasidone ascorbate form I, ascorbate form II and succinate.
  • Figures 5 and 6 are superimposed X-ray patterns of free amine and salt. The patterns show significant differences which confirm the formation of ziprasidone salt.
  • Tables 1 , 2 and 3 present structural data for the salts obtained.
  • IR spectra of the tested samples were measured using Nicolett 6700 apparatus with a liquid-nitrogen cooled MCT detector. The samples were diluted with KBr (1 :100) and pressed at a pressure of 7 tons. Transmittance measurements of the tested samples were taken between 4000-400 cm-1 . The resulting IR spectra are presented in fig. 7, 8, 9 and 10.
  • thermogravimetry analysis was conducted using TGA 2950 HR V5.4A apparatus in the following conditions: Al crucible, analytical sample 14.765 ⁇ 17.953 mg; temperature range between 25°C and 900°C, heating rate 10 K/min, N2 atmosphere (100 cm3/min).
  • the same samples were also subjected to DSC analysis using 2920 MDSC V2.6A apparatus, for determining characteristic temperatures.
  • the following conditions were used: Al crucible, analytical sample 4.460 ⁇ 6.136 mg, temperature range between 25 and 250°C, heating rate 10 K/min, N2 atmosphere (50 cm3/min).
  • the DSC curves obtained are given in figures 1 1 , 12 and 13.
  • succinate is about 10 times more soluble than the base and about 2 times more soluble than the hydrochloride. A similar rise in solubility was also observed for the ascorbate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des nouveaux sels de ziprasidone et leurs solvates ont été divulgués, notamment sous forme cristalline. L'invention concerne plus spécifiquement un sel de ziprasidone choisi dans un groupe comprenant succinate de ziprasidone et ascorbate de ziprasidone, un procédé de fabrication du sel de ziprasodine et une composition pharmaceutique comprenant ledit sel.
PCT/EP2011/062080 2010-07-14 2011-07-14 Nouveaux sels de ziprasidone et leur méthodes de formation WO2012007555A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP391810 2010-07-14
PL391810A PL391810A1 (pl) 2010-07-14 2010-07-14 Nowe sole ziprasidonu oraz sposoby ich otrzymywania

Publications (2)

Publication Number Publication Date
WO2012007555A2 true WO2012007555A2 (fr) 2012-01-19
WO2012007555A3 WO2012007555A3 (fr) 2012-03-15

Family

ID=44630161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/062080 WO2012007555A2 (fr) 2010-07-14 2011-07-14 Nouveaux sels de ziprasidone et leur méthodes de formation

Country Status (2)

Country Link
PL (1) PL391810A1 (fr)
WO (1) WO2012007555A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
PL157897B1 (pl) 1987-03-02 1992-07-31 Pfizer Sposób wytwarzania nowych zwiazków arylopiperazynylo-etylo/lub butylo/-heterocyklicznych PL PL PL
EP0584903A1 (fr) 1992-08-26 1994-03-02 Pfizer Inc. Procédé de préparation de dérivés aryl pipérazinyl-hétérocycliques
EP0586191A1 (fr) 1992-09-01 1994-03-09 Pfizer Inc. Monohydrate du chlorhydrate de 5-(2-(4-(1,2 benzisothiazole-3 YL)-1-pipérazinyl)-éthyl)-6-chloro-1,3-dihydro-2H-indol-2-one
EP0706524A1 (fr) 1993-06-28 1996-04-17 Pfizer Inc. Procedes et intermediaires pour la preparation de 5- 2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
EP0790236A1 (fr) 1996-02-13 1997-08-20 Pfizer Inc. Prodrogues de 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526221A (en) * 2003-09-02 2005-08-16 Imran Ahmed Sustained release dosage forms of ziprasidone
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL157897B1 (pl) 1987-03-02 1992-07-31 Pfizer Sposób wytwarzania nowych zwiazków arylopiperazynylo-etylo/lub butylo/-heterocyklicznych PL PL PL
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
EP0584903A1 (fr) 1992-08-26 1994-03-02 Pfizer Inc. Procédé de préparation de dérivés aryl pipérazinyl-hétérocycliques
EP1029861A1 (fr) 1992-08-26 2000-08-23 Pfizer Inc. Dérivé de benzisothiazolyl-pipérazine et son utilisation comme neuroleptique
EP0586191A1 (fr) 1992-09-01 1994-03-09 Pfizer Inc. Monohydrate du chlorhydrate de 5-(2-(4-(1,2 benzisothiazole-3 YL)-1-pipérazinyl)-éthyl)-6-chloro-1,3-dihydro-2H-indol-2-one
EP0706524A1 (fr) 1993-06-28 1996-04-17 Pfizer Inc. Procedes et intermediaires pour la preparation de 5- 2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
EP0790236A1 (fr) 1996-02-13 1997-08-20 Pfizer Inc. Prodrogues de 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one

Also Published As

Publication number Publication date
PL391810A1 (pl) 2012-01-16
WO2012007555A3 (fr) 2012-03-15

Similar Documents

Publication Publication Date Title
JP5870220B2 (ja) ５−（｛［２−アミノ−３−（４−カルバモイル−２，６−ジメチル−フェニル）−プロピオニル］−［１−（４−フェニル−１ｈ−イミダゾール−２−イル）−エチル］−アミノ｝−メチル）−２−メトキシ−安息香酸の新規な結晶及び製造方法
TWI738748B (zh) 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形
BG64508B1 (bg) Кристален полиморфен (+)-(s)- клопидогрел хидрогенсулфат, метод за получаването му и фармацевтичен състав, който го съдържа
CA2782515A1 (fr) Formes polymorphes de chlorhydrate de 1-¬4-(5-cyanoindol-3-yl)butyl|-4-(2-carbamoylbenzofuran-5-yl)piperazi ne
JP2008509953A (ja) ４−［［（７ｒ）−８−シクロペンチル−７−エチル−５，６，７，８−テトラヒドロ−５−メチル−４−６−オキソ−２−ピペリジニル］アミノ］−３−メトキシ−ｎ−（１−メチル−４−ピペリジニル）ベンズアミドの水和物及び多形、その製造方法、並びにその薬物としての使用
JP5405311B2 (ja) ｍＧｌｕＲ５受容体アンタゴニストの多形
SK282837B6 (sk) Dihydrát metánsulfonátu 5-(2-(4-(1,2-benzizotiazol-3-yl)-1- piperazinyl)etyl)-6-chlór-1,3-dihydro-2H-indol-2-ónu, jeho použitie a farmaceutická kompozícia na jeho báze
JP2023082086A (ja) キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用
JP7168447B2 (ja) ビラスチンの結晶形態及びそれらの調製方法
KR102402501B1 (ko) 피마살탄 트로메타민염 및 이를 포함하는 약제학적 조성물
KR20130136544A (ko) 아고멜라틴의 신규한 결정성 형태 vii, 및 이의 제조 방법 및 용도 및 이를 함유하는 약학적 조성물
ZA200500372B (en) Novel salt and polymorphs of desloratadine hemifumarate
CN115385893A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
CZ20031397A3 (cs) Nové krystalické a solvatované formy ondansetron hydrochloridu a způsoby jejich přípravy
WO2012007555A2 (fr) Nouveaux sels de ziprasidone et leur méthodes de formation
TW442484B (en) New polymorphic form of doxazosin mesylate (form III)
RU2600929C2 (ru) Полиморфы дейтерированной омега-дифенилмочевины или ее солей
CN107663166A (zh) 洛美他派及其制备方法和用途
EP3315493B1 (fr) Composé de phénylamino pyrimidine ou polymorphe d'un sel de ce dernier
US20210179585A1 (en) Crystal form of abemaciclib mesylate, preparation method therefor and pharmaceutical composition thereof
JP2022508864A (ja) チロシンキナーゼ阻害剤のマレイン酸塩の結晶形及びその調製方法
JP2707012B2 (ja) Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
WO2015028828A1 (fr) Sels de sorafénib
MXPA01012328A (es) Polimorfos de un citrato de (2-benzhidril- 1-azabiciclo(2.2.2) oct-3-il- (5-iso- propil-2- metoxibencil) -amina como antagonistas del receptor de nk-1.
CN116041323A (zh) Sigma-1受体激动剂的酸式盐、其晶型及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11743469

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11743469

Country of ref document: EP

Kind code of ref document: A2